Key Points
-
Erythropoietin production is controlled by hypoxia inducible factor (HIF); the prolyl hydroxylase domain-containing (PHD) enzymes regulate HIF and act as molecular oxygen sensors
-
Small-molecule inhibitors of the PHD enzymes increase erythropoietin production and are in clinical development for the treatment of renal anaemia
-
Advantages of PHD enzyme inhibitors over conventional erythropoiesis-stimulating agents (ESAs) include oral administration, lower production costs, product stability and low immunogenicity
-
PHD enzyme inhibitors have effects besides increasing production of erythropoietin. Some of these effects could be beneficial, including improvements in uptake and utilization of iron
-
The balance of risks and benefits in treating renal anaemia with PHD enzyme inhibitors is currently being addressed in randomized controlled trials
-
PHD inhibitors might be useful for therapeutic indications other than the management of renal anaemia
Abstract
Small-molecule stabilizers of hypoxia inducible factor (HIF) are being developed for the treatment of renal anaemia. These molecules inhibit prolyl hydroxylase domain-containing (PHD) enzymes, resulting in HIF activation and increased production of erythropoietin. Currently, renal anaemia is treated with recombinant human erythropoietin or related analogues, referred to as conventional erythropoiesis stimulating agents (ESAs). Advantages of PHD enzyme inhibitors over conventional ESAs include their oral administration and their simpler — and potentially cheaper — production. Importantly, inhibition of PHD enzymes is likely to have a range of consequences other than increasing levels of erythropoietin, and these effects could be beneficial — for instance by reducing the need for parenteral iron — but might in some instances be harmful. Several companies are currently testing PHD enzyme inhibitors in patients with renal anaemia and have reported clear evidence of efficacy without serious safety concerns. A central question that current studies are beginning to address is whether using PHD enzyme inhibitors will influence hard end points, including mortality and the rate of cardiovascular events. In terms of approaches to therapy, the exquisite specificity of conventional ESAs is a striking contrast to the pleiotropic effects of activating HIF. Excitingly, PHD inhibitors could also be useful for conditions besides renal anaemia, such as protection from ischaemic injury.
Similar content being viewed by others
References
Semenza, G. L. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu. Rev. Pathol. 9, 47–71 (2014).
Chowdhury, R. et al. Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases. ACS Chem. Biol. 8, 1488–1496 (2013).
Rabinowitz, M. H. Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses. J. Med. Chem. 56, 9369–9402 (2013).
Macdougall, I. C. & Obrador, G. T. How important is transfusion avoidance in 2013? Nephrol. Dial. Transplant. 28, 1092–1099 (2013).
Winearls, C. G. et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2, 1175–1178 (1986).
Palmer, S. C. et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst. Rev. 12, CD010590 (2014).
Palmer, S. C., Saglimbene, V., Craig, J. C., Navaneethan, S. D. & Strippoli, G. F. Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database Syst. Rev. 3, CD009297 (2014).
Macdougall, I. C. et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N. Engl. J. Med. 368, 320–332 (2013).
Fishbane, S. et al. Peginesatide in patients with anemia undergoing hemodialysis. N. Engl. J. Med. 368, 307–319 (2013).
Macdougall, I. C. et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N. Engl. J. Med. 361, 1848–1855 (2009).
Kaushik, T. & Yaqoob, M. M. Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis. Biologics 7, 243–246 (2013).
Eckardt, K. U. Anaemia: the safety and efficacy of peginesatide in patients with CKD. Nat. Rev. Nephrol. 9, 192–193 (2013).
Babitt, J. L. & Lin, H. Y. Mechanisms of anemia in CKD. J. Am. Soc. Nephrol. 23, 1631–1634 (2012).
Rossert, J., Casadevall, N. & Eckardt, K. U. Anti-erythropoietin antibodies and pure red cell aplasia. J. Am. Soc. Nephrol. 15, 398–406 (2004).
Macdougall, I. C. et al. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol. Dial. Transplant. 30, 451–460 (2015).
Pfeffer, M. A. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019–2032 (2009).
Singh, A. K. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085–2098 (2006).
Zarychanski, R. & Houston, D. S. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ 179, 333–337 (2008).
Manns, B. J. & Tonelli, M. The new FDA labeling for ESA — implications for patients and providers. Clin. J. Am. Soc. Nephrol. 7, 348–353 (2012).
KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2, 279–335 (2012).
Epstein, A. C. et al. C. elegans EGL-9 and mammalian homologues define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43–54 (2001).
Laitala, A. et al. Transmembrane prolyl 4-hydroxylase is a fourth prolyl 4-hydroxylase regulating EPO production and erythropoiesis. Blood 120, 3336–3344 (2012).
Rose, N. R., McDonough, M. A., King, O. N., Kawamura, A. & Schofield, C. J. Inhibition of 2-oxoglutarate dependent oxygenases. Chem. Soc. Rev. 40, 4364–4397 (2011).
Johansson, C. et al. The roles of Jumonji-type oxygenases in human disease. Epigenomics 6, 89–120 (2014).
Feng, T. et al. Optimal translational termination requires C4 lysyl hydroxylation of eRF1. Mol. Cell 53, 645–654 (2014).
Singleton, R. S. et al. OGFOD1 catalyzes prolyl hydroxylation of RPS23 and is involved in translation control and stress granule formation. Proc. Natl Acad. Sci. USA 111, 4031–4036 (2014).
Walport, L. J. et al. Human UTY(KDM6C) is a male-specific Nε-methyl lysyl demethylase. J. Biol. Chem. 289, 18302–18313 (2014).
Liu, L. et al. Hairless is a histone H3K9 demethylase. FASEB J. 28, 1534–1542 (2014).
Watanabe, S. et al. JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response to DNA breaks. Nat. Struct. Mol. Biol. 20, 1425–1433 (2013).
Masson, N., Willam, C., Maxwell, P. H., Pugh, C. W. & Ratcliffe, P. J. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J. 20, 5197–5206 (2001).
Hirsila, M., Koivunen, P., Gunzler, V., Kivirikko, K. I. & Myllyharju, J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J. Biol. Chem. 278, 30772–30780 (2003).
Lando, D. et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16, 1466–1471 (2002).
Schodel, J. et al. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 117, e207–e217 (2011).
Scholz, C. C. et al. Regulation of IL-1β-induced NF-κB by hydroxylases links key hypoxic and inflammatory signaling pathways. Proc. Natl Acad. Sci. USA 110, 18490–18495 (2013).
Coleman, M. L. et al. Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor. J. Biol. Chem. 282, 24027–24038 (2007).
Yang, M. et al. Asparagine and aspartate hydroxylation of the cytoskeletal ankyrin family is catalyzed by factor-inhibiting hypoxia-inducible factor. J. Biol. Chem. 286, 7648–7660 (2011).
Maxwell, P. H. et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int. 44, 1149–1162 (1993).
Bachmann, S., Le Hir, M. & Eckardt, K.-U. Co-localization of erythropoietin messenger RNA and ecto-5′-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J. Histochem. Cytochem. 41, 335–341 (1993).
Obara, N. et al. Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 111, 5223–5232 (2008).
Rosenberger, C. et al. Expression of hypoxia-inducible factor-1α and -2α in hypoxic and ischemic rat kidneys. J. Am. Soc. Nephrol. 13, 1721–1732 (2002).
Schietke, R. E. et al. Renal tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cysts. PLoS ONE 7, e31034 (2012).
Scortegagna, M. et al. HIF-2α regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 105, 3133–3140 (2005).
Percy, M. J. et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N. Engl. J. Med. 358, 162–168 (2008).
Gale, D. P., Harten, S. K., Reid, C. D., Tuddenham, E. G. & Maxwell, P. H. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2α mutation. Blood 112, 919–921 (2008).
Beall, C. M. et al. Natural selection on EPAS1 (HIF2α) associated with low hemoglobin concentration in Tibetan highlanders. Proc. Natl Acad. Sci. USA 107, 11459–11464 (2010).
Yi, X. et al. Sequencing of 50 human exomes reveals adaptation to high altitude. Science 329, 75–78 (2010).
Berra, E. et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J. 22, 4082–4090 (2003).
Appelhoff, R. J. et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J. Biol. Chem. 279, 38458–38465 (2004).
Percy, M. J. et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc. Natl Acad. Sci. USA 103, 654–659 (2006).
Zhang, N. et al. The asparaginyl hydroxylase factor inhibiting HIF-1α is an essential regulator of metabolism. Cell. Metab. 11, 364–378 (2010).
Takeda, K. et al. Placental but not heart defect is associated with elevated HIFα levels in mice lacking prolyl hydroxylase domain protein 2. Mol. Cell. Biol. 26, 8336–8346 (2006).
Cunliffe, C. J., Franklin, T. J., Hales, N. J. & Hill, G. B. Novel inhibitors of prolyl 4-hydroxylase. 3. Inhibition by the substrate analogue N-oxaloglycine and its derivatives. J. Med. Chem. 35, 2652–2658 (1992).
Majamaa, K., Gunzler, V., Hanauske-Abel, H. M., Myllyla, R. & Kivirikko, K. I. Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase. J. Biol. Chem. 261, 7819–7823 (1986).
Jaakkola, P. et al. Targeting of HIF-α to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468–472 (2001).
Ivan, M. et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc. Natl Acad. Sci. USA 99, 13459–13464 (2002).
Hsieh, M. M. et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 110, 2140–2147 (2007).
Flamme, I. et al. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85–3934 (molidustat) stimulates erythropoietin production without hypertensive effects. PLoS ONE 9, e111838 (2014).
Maxwell, P. H., Ferguson, D. J., Nicholls, L. G., Johnson, M. H. & Ratcliffe, P. J. The interstitial response to renal injury: fibroblast-like cells show phenotypic changes and have reduced potential for erythropoietin gene expression. Kidney Int. 52, 715–724 (1997).
Souma, T. et al. Plasticity of renal erythropoietin-producing cells governs fibrosis. J. Am. Soc. Nephrol. 24, 1599–1616 (2013).
Chiang, C. K., Tanaka, T., Inagi, R., Fujita, T. & Nangaku, M. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab. Invest. 91, 1564–1571 (2011).
Wu, I. W. et al. Oral adsorbent AST-120 potentiates the effect of erythropoietin-stimulating agents on stage 5 chronic kidney disease patients: a randomized crossover study. Nephrol. Dial. Transplant. 29, 1719–1727 (2014).
Blumberg, A., Keller, H. & Marti, H. R. Effect of altitude on erythropoiesis and oxygen affinity in anaemic patients on maintenance dialysis. Eur. J. Clin. Invest. 3, 93–97 (1973).
Chandra, M., Clemons, G. K. & McVicar, M. I. Relation of serum erythropoietin levels to renal excretory function: evidence for lowered set point for erythropoietin production in chronic renal failure. J. Pediatr. 113, 1015–1021 (1988).
Walle, A. J., Wong, G. Y., Clemons, G. K., Garcia, J. F. & Niedermayer, W. Erythropoietin–hematocrit feedback circuit in the anemia of end-stage renal disease. Kidney Int. 31, 1205–1209 (1987).
Brookhart, M. A. et al. The effect of altitude on dosing and response to erythropoietin in ESRD. J. Am. Soc. Nephrol. 19, 1389–1395 (2008).
Aeberhard, J.-M., Schneider, P.-A., Vallotton, M. B., Kurtz, A. & Leski, M. Multiple site estimates of erythropoietin and renin in polycythemic kidney transplant patients. Transplantation 50, 613–616 (1990).
Malyszko, J., Oberbauer, R. & Watschinger, B. Anemia and erythrocytosis in patients after kidney transplantation. Transpl. Int. 25, 1013–1023 (2012).
Eckardt, K.-U. et al. Erythropoietin in polycystic kidneys. J. Clin. Invest. 84, 1160–1166 (1989).
Shalhoub, R. J., Rajan, U., Goldwasser, E., Karak, J. A. & Antoniou, L. D. Erythrocytosis in patients on long-term hemodialysis. Ann. Int. Med. 97, 686–690 (1982).
Bernhardt, W. M. et al. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am. J. Pathol. 170, 830–842 (2007).
Buchholz, B. et al. Hypoxia-inducible factor-1α causes renal cyst expansion through calcium-activated chloride secretion. J. Am. Soc. Nephrol. 25, 465–474 (2014).
Koury, S. T., Bondurant, M. C., Koury, M. J. & Semenza, G. L. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 77, 2497–2503 (1991).
Maxwell, P. H. et al. Expression of a homologously recombined erythropoietin-SV40 T antigen fusion gene in mouse liver: evidence for erythropoietin production by Ito cells. Blood 84, 1823–1830 (1994).
Eckardt, K.-U., Ratcliffe, P. J., Tan, C. C., Bauer, C. & Kurtz, A. Age-dependent expression of the erythropoietin gene in rat liver and kidneys. J. Clin. Invest. 89, 753–760 (1992).
Kolk-Vegter, A. J., Bosch, E. & van Leeuwen, A. M. Influence of serum hepatitis on haemoglobin level in patients on regular haemodialysis. Lancet 1, 526–528 (1971).
Naughton, B. A. et al. Hepatic regeneration and erythropoietin production in the rat. Science 196, 301–302 (1977).
Suzuki, N. et al. Specific contribution of the erythropoietin gene 3′ enhancer to hepatic erythropoiesis after late embryonic stages. Mol. Cell. Biol. 31, 3896–3905 (2011).
Tojo, Y. et al. Hypoxia signaling cascade for erythropoietin production in hepatocytes. Mol. Cell. Biol. 35, 2658–2672 (2015).
Minamishima, Y. A. & Kaelin, W. G. Jr. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science 329, 407 (2010).
Weidemann, A. et al. The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice. J. Clin. Invest. 119, 3373–3383 (2009).
Rankin, E. B. et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell 149, 63–74 (2012).
Jelkmann, W. Erythropoietin: structure, control of production, and function. Physiol. Rev. 72, 449–489 (1992).
Beyer, S., Kristensen, M. M., Jensen, K. S., Johansen, J. V. & Staller, P. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J. Biol. Chem. 283, 36542–36552 (2008).
Bhatt, K. et al. MicroRNA-687 induced by hypoxia-inducible factor-1 targets phosphatase and tensin homolog in renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 26, 1588–1596 (2015).
Sun, C. C., Vaja, V., Babitt, J. L. & Lin, H. Y. Targeting the hepcidin–ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am. J. Hematol. 87, 392–400 (2012).
Kim, A. & Nemeth, E. New insights into iron regulation and erythropoiesis. Curr. Opin. Hematol. 22, 199–205 (2015).
Shah, Y. M. & Xie, L. Hypoxia-inducible factors link iron homeostasis and erythropoiesis. Gastroenterology 146, 630–642 (2014).
Peyssonnaux, C. et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J. Clin. Invest. 117, 1926–1932 (2007).
Liu, Q., Davidoff, O., Niss, K. & Haase, V. H. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J. Clin. Invest. 122, 4635–4644 (2012).
Volke, M. et al. Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors. PLoS ONE 4, e7875 (2009).
Brigandi, R. A. et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [poster SA-PO117]. J. Am. Soc. Nephrol. 23 (Abstract suppl.), 663A (2012).
Shalwitz, R. et al. AKB-6548, a new hypoxia-inducible factor prolyl hydroxylase inhibitor, increases hemoglobin in chronic kidney disease patients without increasing basal erythropoietin levels [abstract FR-OR116]. J. Am. Soc. Nephrol. 23 (Abstract suppl.), 56A (2012).
Besarab, A., Szczech, L., Yu, K.-H. P. & Neff, T. B. Impact of iron regimen on iron indices and hepcidin during roxadustat anemia correction in incident dialysis patients [poster TH-PO847]. J. Am. Soc. Nephrol. 25 (Abstract suppl.), 304A (2014).
Ashby, D. R. et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 95, 505–508 (2010).
Ashby, D. R. et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 75, 976–981 (2009).
Gammella, E. et al. Erythropoietin's inhibiting impact on hepcidin expression occurs indirectly. Am. J. Physiol. Regul. Integr. Comp. Physiol. 308, R330–R335 (2015).
Olson, E. et al. Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease. Vasc. Med. 19, 473–482 (2014).
Hill, P. et al. Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 19, 39–46 (2008).
Gossage, L., Eisen, T. & Maher, E. R. VHL, the story of a tumour suppressor gene. Nat. Rev. Cancer 15, 55–64 (2015).
Gnarra, J. R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85–90 (1994).
Raval, R. R. et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel–Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25, 5675–5686 (2005).
Mandriota, S. J. et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459–468 (2002).
Kondo, K., Kim, W., Lechpammer, M. & Kaelin, W. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, 439–444 (2003).
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
Frew, I. J. et al. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J. 27, 1747–1757 (2008).
Clifford, S. C. et al. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel–Lindau disease. Hum. Mol. Genet. 10, 1029–1038 (2001).
Jochmanova, I., Zelinka, T., Widimsky, J. Jr & Pacak, K. HIF signaling pathway in pheochromocytoma and other neuroendocrine tumors. Physiol. Res. 63, S251–S262 (2014).
Yang, C. et al. Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. J. Mol. Med. (Berl.) 93, 93–104 (2015).
Pugh, C. W. & Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9, 677–684 (2003).
Kaelin, W. G. Jr. Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb. Symp. Quant. Biol. 76, 335–345 (2011).
Barriga, E. H., Maxwell, P. H., Reyes, A. E. & Mayor, R. The hypoxia factor Hif-1α controls neural crest chemotaxis and epithelial to mesenchymal transition. J. Cell Biol. 201, 759–776 (2013).
Esteban, M. A. et al. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res. 66, 3567–3575 (2006).
Higgins, D. F. et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J. Clin. Invest. 117, 3810–3820 (2007).
Semenza, G. L. Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol. Med. 18, 534–543 (2012).
Ang, S. O. et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat. Genet. 32, 614–621 (2002).
Percy, M. J. et al. Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood 111, 5400–5402 (2008).
Bond, J. et al. Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension. Blood 117, 3699–3701 (2011).
Smith, T. G. et al. Mutation of von Hippel–Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med. 3, e290 (2006).
Hickey, M. M. et al. The von Hippel–Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J. Clin. Invest. 120, 827–839 (2010).
Gordeuk, V. R. et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 103, 3924–3932 (2004).
Imanishi, M. et al. Smooth muscle cell-specific Hif-1α deficiency suppresses angiotensin II-induced vascular remodelling in mice. Cardiovasc. Res. 102, 460–468 (2014).
Parathath, S. et al. Hypoxia is present in murine atherosclerotic plaques and has multiple adverse effects on macrophage lipid metabolism. Circ. Res. 109, 1141–1152 (2011).
Tanaka, T. et al. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab. Invest. 85, 1292–1307 (2005).
Tanaka, T. et al. Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis. Kidney Int. 68, 2714–2725 (2005).
Song, Y. R. et al. Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney. Nephrol. Dial. Transplant. 25, 77–85 (2010).
Kobayashi, H. et al. Myeloid cell-derived hypoxia-inducible factor attenuates inflammation in unilateral ureteral obstruction-induced kidney injury. J. Immunol. 188, 5106–5115 (2012).
Nordquist, L. et al. Activation of hypoxia-inducible factors prevents diabetic nephropathy. J. Am. Soc. Nephrol. 26, 328–338 (2015).
Bernhardt, W. M. et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J. Am. Soc. Nephrol. 21, 2151–2156 (2010).
Besarab, A. et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol. Dial. Transplant. 30, 1665–1673 (2015).
Besarab, A. et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2015030241 (2015).
Boettcher, M.-F., Lentini, S., Flamme, I., Kubitza, D. & Wensing, G. First-in-Man study with BAY 85-3934 — a new oral selective HIF-PH inhibitor for the treatment of renal anemia [poster TH-PO1090]. J. Am. Soc. Nephrol. 24 (Abstract suppl.), 347A (2013).
Holdstock, L. et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2014111139 (2015).
McCafferty, K., Forbes, S., Thiemermann, C. & Yaqoob, M. M. The challenge of translating ischemic conditioning from animal models to humans: the role of comorbidities. Dis. Model Mech. 7, 1321–1333 (2014).
Sheldon, R. A., Lee, C. L., Jiang, X., Knox, R. N. & Ferriero, D. M. Hypoxic preconditioning protection is eliminated in HIF-1α knockout mice subjected to neonatal hypoxia-ischemia. Pediatr. Res. 76, 46–53 (2014).
Sarkar, K. et al. Hypoxia-inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning. Proc. Natl Acad. Sci. USA 109, 10504–10509 (2012).
Chen, R. L. et al. HIF prolyl hydroxylase inhibition prior to transient focal cerebral ischaemia is neuroprotective in mice. J. Neurochem. 131, 177–189 (2014).
Vogler, M. et al. Pre- and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes protects the heart from an ischemic insult. Pflugers Arch. 467, 2141–2149 (2015).
Ong, S. G. et al. HIF-1 reduces ischaemia-reperfusion injury in the heart by targeting the mitochondrial permeability transition pore. Cardiovasc. Res. 104, 24–36 (2014).
Lijkwan, M. A. et al. Short hairpin RNA gene silencing of prolyl hydroxylase-2 with a minicircle vector improves neovascularization of hindlimb ischemia. Hum. Gene Ther. 25, 41–49 (2014).
Aragones, J. et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat. Genet. 40, 170–180 (2008).
Matsumoto, M. et al. Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J. Am. Soc. Nephrol. 14, 1825–1832 (2003).
Bernhardt, W. M. et al. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J. Am. Soc. Nephrol. 17, 1970–1978 (2006).
Wang, Z. et al. The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior to ischaemia but is superior to EPO treatment. Nephrol. Dial. Transplant. 27, 929–936 (2012).
Bernhardt, W. M. et al. Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model. Proc. Natl Acad. Sci. USA 106, 21276–21281 (2009).
Pearl, R. G. Erythropoietin and organ protection: lessons from negative clinical trials. Crit. Care 18, 526 (2014).
Nauta, T. D., van Hinsbergh, V. W. & Koolwijk, P. Hypoxic signaling during tissue repair and regenerative medicine. Int. J. Mol. Sci. 15, 19791–19815 (2014).
Acknowledgements
The authors are grateful to Matthew Coleman (University of Birmingham, UK) for expert input into Supplementary Table 1, and to Akebia, GlaxoSmithKline, AstraZeneca and Bayer for providing information about ongoing clinical trials. Representatives of these companies had no influence on the content of this article. We recognize that not all scientific papers that relate to the topic of this Review could be included and apologize for the omission of any important contributions.
Author information
Authors and Affiliations
Contributions
Both authors researched data for the article and wrote the article.
Corresponding author
Ethics declarations
Competing interests
P.H.M. is the scientific founder, a shareholder and director of ReOx. K.-U.E. has received consultancy fees from companies that produce or distribute therapeutics for management of anaemia, including Akebia, Amgen, AstraZeneca, Johnson & Johnson, Roche, Sandoz, Takeda and Vifor. He has also received grant support from Amgen and Bayer for the German Chronic Kidney Disease (GCKD) study.
Supplementary information
Supplementary Table 1
Human 2-oxoglutarate oxygenases and their reported associated substrates and human genetic diseases. (DOC 187 kb)
Rights and permissions
About this article
Cite this article
Maxwell, P., Eckardt, KU. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol 12, 157–168 (2016). https://doi.org/10.1038/nrneph.2015.193
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2015.193
- Springer Nature Limited
This article is cited by
-
Prolyl hydroxylase domain inhibitor is an effective pre-hospital pharmaceutical intervention for trauma and hemorrhagic shock
Scientific Reports (2024)
-
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
Nature Reviews Drug Discovery (2023)
-
HIF-PHD inhibitor regulates the function of group2 innate lymphoid cells and polarization of M2 macrophages
Scientific Reports (2023)
-
Activation of HIF-1α C-terminal transactivation domain protects against hypoxia-induced kidney injury through hexokinase 2-mediated mitophagy
Cell Death & Disease (2023)
-
Prolylhydroxylaseinhibitoren – „new kids in the blood“
Die Nephrologie (2023)